Summit Therapeutics Inc. (SMMT) Stock Price, Financial Report, & Fundamental Analysis

Strength

Analysis	#
Net Income Growth SMMT has had growing net income for the last 2 years
Debt-Equity Ratio (DER) SMMT equity is higher than it's debt.
Revenue SMMT has positive revenue for last 5 years

Weakness

Analysis	#
Market Cap Small market capitalization. Market capitalization is less than 2bn USD
Revenue Growth SMMT has never had growing revenue.
Price to Book (PBV) Ratio Overvalued price-to-book. SMMT stock price is overvalued by more than 2x the price-to-book value.
Net Income SMMT never has positive net income for 2 years.
Dividend Yield SMMT has low dividend yield (0%).
Return of Assets SMMT has low return of asset (-55.79%).
Return of Equity SMMT has low return of equity (-104.32%).
Return of Invested Capital SMMT has low ROIC.

Competitors

Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.

Income Statement

Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.

Cashflow Statement

A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.

Free Cash Flow

-72,587,000 USD

Dividend

Financial Ratios

CEO

CEO Name

Mr. Robert W. Duggan

Management

About Summit Therapeutics Inc.

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Additional Information

Company name

Summit Therapeutics Inc.

Symbol

NASDAQ:SMMT

Exchange

NASDAQ Global Market

Industry

Biotechnology

Sector

Healthcare

Address

136a Eastern Avenue
Abingdon

GB
02142

Website

https://www.summittxinc.com